Trial Outcomes & Findings for Diabetes Remote Care Management System (NCT NCT01354015)

NCT ID: NCT01354015

Last Updated: 2017-05-09

Results Overview

change in A1c from baseline in intervention and control groups

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

98 participants

Primary outcome timeframe

baseline to 6 months

Results posted on

2017-05-09

Participant Flow

01/01/12 from diabetes clinic

Participant milestones

Participant milestones
Measure
Use of Messaging System
Use of DRMS DRMS: USE OF TEXT MESSAGING SYSTEM
Usual Care
Usual Care
Overall Study
STARTED
50
48
Overall Study
COMPLETED
44
43
Overall Study
NOT COMPLETED
6
5

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Diabetes Remote Care Management System

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Use of Messaging System
n=50 Participants
Use of DRMS DRMS: USE OF TEXT MESSAGING SYSTEM
Usual Care
n=48 Participants
Usual Care
Total
n=98 Participants
Total of all reporting groups
Age, Continuous
58.9 years
STANDARD_DEVIATION 10.3 • n=5 Participants
59.3 years
STANDARD_DEVIATION 8.7 • n=7 Participants
59.1 years
STANDARD_DEVIATION 9.5 • n=5 Participants
Sex: Female, Male
Female
34 Participants
n=5 Participants
25 Participants
n=7 Participants
59 Participants
n=5 Participants
Sex: Female, Male
Male
16 Participants
n=5 Participants
23 Participants
n=7 Participants
39 Participants
n=5 Participants
Race/Ethnicity, Customized
American Indian or Alaska Native
0 participants
n=5 Participants
0 participants
n=7 Participants
0 participants
n=5 Participants
Race/Ethnicity, Customized
Asian
0 participants
n=5 Participants
1 participants
n=7 Participants
1 participants
n=5 Participants
Race/Ethnicity, Customized
Native Hawaiian or Other Pacific Islander
0 participants
n=5 Participants
0 participants
n=7 Participants
0 participants
n=5 Participants
Race/Ethnicity, Customized
Black or African American
37 participants
n=5 Participants
27 participants
n=7 Participants
64 participants
n=5 Participants
Race/Ethnicity, Customized
White
13 participants
n=5 Participants
17 participants
n=7 Participants
30 participants
n=5 Participants
Race/Ethnicity, Customized
More than one race
0 participants
n=5 Participants
0 participants
n=7 Participants
0 participants
n=5 Participants
Race/Ethnicity, Customized
Unknown or Not Reported
0 participants
n=5 Participants
3 participants
n=7 Participants
3 participants
n=5 Participants

PRIMARY outcome

Timeframe: baseline to 6 months

Population: Of the 50 enrolled in the Use of DRMS group, only 44 completed the visit at 6 months, and out of 48 enrolled in the Usual Care group only 43 completed the visit at 6 months. Therefore only those who completed the visit at 6 months were included in this analysis.

change in A1c from baseline in intervention and control groups

Outcome measures

Outcome measures
Measure
Use of Messaging System
n=44 Participants
Use of DRMS DRMS: USE OF TEXT MESSAGING SYSTEM
Usual Care
n=43 Participants
Usual Care
Change in HbA1c
-0.25 Percent
Standard Deviation 0.2
-0.4 Percent
Standard Deviation 0.3

SECONDARY outcome

Timeframe: baseline to 3 months

Population: Of the 50 enrolled in the Use of DRMS group, only 46 completed the visit at 3 months, and out of 48 enrolled in the Usual Care group only 45 completed the visit at 3 months. Therefore only those who completed the visit at 3 months were included in this analysis.

Change in HbA1c

Outcome measures

Outcome measures
Measure
Use of Messaging System
n=46 Participants
Use of DRMS DRMS: USE OF TEXT MESSAGING SYSTEM
Usual Care
n=45 Participants
Usual Care
Change in HbA1c Over 3 Months
-0.5 Percent
Standard Deviation 0.3
-0.2 Percent
Standard Deviation 0.2

Adverse Events

Use of Messaging System

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Usual Care

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr Vivian Fonseca

Tulane University

Phone: 5049884026

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place